Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 7:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Twice Weekly Clear all
Completed Phase 2 Interventional

Pain Associated With Endometriosis

NCT00758953
View directory record Official record
Conditions
Endometriosis
Interventions
Danazol Once Weekly, Danazol Twice Weekly, Placebo Once Weekly, Placebo Twice Weekly
Drug
Lead sponsor
Lumara Health, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
38
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Sep 28, 2026, 7:29 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)

NCT02213757
View directory record Official record
Conditions
Microscopic Hematuria
Interventions
Premarin vaginal estrogen cream, Placebo vaginal cream
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Results available

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

NCT01610596
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Halobetasol Propionate Lotion 0.05%, Placebo
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
San Diego, California • Fridley, Minnesota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Results available

Buprenorphine's Dose Response Curve

NCT00460239
View directory record Official record
Conditions
Opioid-related Disorders
Interventions
Buprenorphine, Morphine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effects of Anorexia Nervosa on Peak Bone Mass

NCT01301183
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
RhIGF-1 with transdermal 17-beta estradiol, Placebo and transdermal 17-beta estradiol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 22 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)

NCT00421174
View directory record Official record
Conditions
Pneumonia, Idiopathic Pneumonia Syndrome
Interventions
Etanercept, Placebo plus corticosteroid
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
12
States / cities
Gainesville, Florida • Indianapolis, Indiana • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

NCT01052662
View directory record Official record
Conditions
Opioid Dependence
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 25 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 2 Interventional

Pioglitazone as an Adjunct to Cognitive-Behavioral Therapy for Cocaine Relapse Prevention

NCT04843046
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Cognitive Behavioral Therapy (CBT), Pioglitazone, Placebo
Behavioral · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 28, 2026, 7:29 AM EDT
Recruiting Phase 2 Interventional

Milk Thistle Clinical Trial in Pediatric NAFLD

NCT06477146
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions
Milk thistle (MT), Placebo, Lifestyle Modification, Fibroscan
Drug · Behavioral · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
9 Years to 22 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 28, 2026, 7:29 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

NCT01732913
View directory record Official record
Conditions
Indolent Non-Hodgkin's Lymphomas
Interventions
Placebo, Rituximab, Idelalisib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
32
States / cities
Huntsville, Alabama • Chandler, Arizona • Duarte, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 28, 2026, 7:29 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

NCT05059262
View directory record Official record
Conditions
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
Interventions
Vimseltinib, Placebo
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
11
States / cities
Duarte, California • Sacramento, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Not applicable Interventional

Improving New Learning and Memory in Traumatic Brain Injury

NCT01207375
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
memory retraining exercises, placebo control memory exercises
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 59 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Sep 28, 2026, 7:29 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus

NCT02439957
View directory record Official record
Conditions
Cytomegalovirus Disease, Kidney Transplant Infection
Interventions
Brincidofovir, Valganciclovir
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 28, 2026, 7:29 AM EDT
Recruiting Phase 2 Interventional

Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD

NCT05928936
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sodium Bicarbonate, Exercise Training, Placebo
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
40 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 4 Interventional Results available

DECIFER: Depression and Citalopram In First Episode Recovery

NCT01041274
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder
Interventions
Citalopram, Placebo, Psychoeducation, Cognitive Behavioral Therapy (CBT), Functional Magnetic Resonance Imaging (fMRI)
Drug · Behavioral · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 40 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Not applicable Interventional

Music Therapy to Prevent Hospital-acquired Delirium in Parkinson's Disease and Dementia With Lewy Bodies

NCT06063161
View directory record Official record
Conditions
Parkinson Disease, Dementia, Lewy Body, Delirium
Interventions
Music therapy intervention, Standard Care (in control arm)
Behavioral · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Results available

Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients

NCT00942305
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Brincidofovir, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Not applicable Interventional Results available

Effect of Acupuncture on Patient Vulvodynia Outcomes

NCT03364127
View directory record Official record
Conditions
Vulvodynia, Vulvodynia, Generalized, Vulvar Vestibulitis
Interventions
Active Acupuncture, Placebo Acupuncture
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 28, 2026, 7:29 AM EDT
Not listed Not applicable Interventional

Negative Work Exercise for the Treatment of Knee Arthritis

NCT02098096
View directory record Official record
Conditions
Osteoarthritis, Arthritis
Interventions
Negative Work, Stretching
Other
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
50 Years to 70 Years · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Sep 28, 2026, 7:29 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Daily Upgrade Trial

NCT07792603
View directory record Official record
Conditions
Healthy Women
Interventions
Essential Amino Acid+, Non-Calorie Placebo, High intensity Interval Training, No Exercise
Dietary Supplement · Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
25 Years to 45 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 28, 2026, 7:29 AM EDT
Terminated Phase 4 Interventional Results available

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

NCT03633227
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
Obeticholic Acid (OCA), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
Rialto, California • Sacramento, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2022 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

NCT00624338
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Atacicept 75 mg, Atacicept 150 mg, Placebo Comparator
Drug · Other
Lead sponsor
EMD Serono
Industry
Eligibility
16 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Results available

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

NCT01257204
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Placebo, Daclatasvir, Pegylated interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Tulsa, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 28, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

NCT01318694
View directory record Official record
Conditions
Hepatitis C
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin, ALV Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Beverly Hills, California • Oakland, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 28, 2026, 7:29 AM EDT